bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 1 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Figure 1 CD171 tissue expression in human shown by TMA.
Supplemental Methods from Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
Authors: Perales-Puchalt Alfredo , Svoronos Nikolaos , Rutkowski Melanie R. , Allegrezza Michael J. , Tesone Amelia J. , Payne Kyle K. , Wickramasinghe Jayamanna , Nguyen Jenny M. , O'Brien Shane W. , Gumireddy Kiranmai , Huang Qihong , Cadungog Mark G. , Connolly Denise C. , Tchou Julia , Curiel Tyler J. , Conejo-Garcia Jose R.
Published: April 2023

Supplemental Methods
Supplementary_Tables from Clonal Structures of Regionally Synchronous Gastric Adenomas and Carcinomas
Authors: Jung Seung-Hyun , Kim Shin Young , An Chang Hyeok , Lee Sung Hak , Jung Eun Sun , Park Hyeon-Chun , Kim Min Sung , Chung Yeun-Jun , Lee Sug Hyung
Published: April 2023

Supplementary Table S1. The description of whole-exome sequencing data Supplementary Table S2. Somatic point mutations and indels identified across 15 synchronous gastric adenoma and gastric carcinom genomes Supplementary Table S3. Copy number alterations identified across 15 synchronous gastric adenoma and gastric carcinom genomes Supplementary Table S4. The description of targeted panel sequencing data Supplementary Table S5. Recurrent regions of copy number alterations
Supplementary Data from The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Authors: Waks Adrienne G. , Stover Daniel G. , Guerriero Jennifer L. , Dillon Deborah , Barry William T. , Gjini Evisa , Hartl Christina , Lo Wesley , Savoie Jennifer , Brock Jane , Wesolowski Robert , Li Zaibo , Damicis Adrienne , Philips Anne V. , Wu Yun , Yang Fei , Sullivan Amy , Danaher Patrick , Brauer Heather Ann , Osmani Wafa , Lipschitz Mikel , Hoadley Katherine A. , Goldberg Michael , Perou Charles M. , Rodig Scott , Winer Eric P. , Krop Ian E. , Mittendorf Elizabeth A. , Tolaney Sara M.
Published: April 2023

Figure S1. REMARK diagram Figure S2. NanoString Tumor Inflammation Signature by breast cancer intrinsic subtype Figure S3. NanoString individual gene expression changes by cohort Table S1. Pre-treatment immune microenvironment and response to preoperative therapy Table S2. Tissue-based immune biomarkers in patients with pathologic complete response Table S3. References for classification of genes as M1-like or M2-like
Figure S1 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

Figure for online supplement
Figure S3A from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Gating strategy for identifying immune cells by CyTOF
Materials and Methods and Figures S1-S6 from T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
Authors: Deniger Drew C. , Pasetto Anna , Robbins Paul F. , Gartner Jared J. , Prickett Todd D. , Paria Biman C. , Malekzadeh Parisa , Jia Li , Yossef Rami , Langhan Michelle M. , Wunderlich John R. , Danforth David N. , Somerville Robert P.T. , Rosenberg Steven A.
Published: April 2023

Additional materials and methods. Figure S1. CD4+ T cells responded to USP9X-Y2009C minimal epitope. Figure S2. CD4+ T cells recognized INPP5K-L272V neoantigen. Figure S3. T cells transduced with TCRs recognize Histone H1.5-A71D neoantigen. Figure S4. CD4+ T cells responded to RAPTOR-D654G minimal neoepitope. Figure S5. The p53-G245S minimal neoepitope was mapped to the N-terminus of the 25 amino acid neoantigen. Figure S6. Peptide parsing from Patient 7 demonstrated CTAGE5-E576V, p53-Y220C and HUWE1-F4353S responses.
Supplementary Information from Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment
Authors: Spencer Noakes T. Leigh , Przybycien Thomas S. , Forwell Amanda , Nicholls Connor , Zhou Yu-Qing , Butcher Darci T. , Weksberg Rosanna , Guger Sharon L. , Spiegler Brenda J. , Schachar Russell J. , Hitzler Johann , Ito Shinya , van der Plas Ellen , Nieman Brian J.
Published: April 2023

Additional figures and tables
Table S1 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

shRNA sequences of constructs used in this study.
Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Authors: Boysen Gunther , Rodrigues Daniel N. , Rescigno Pasquale , Seed George , Dolling David , Riisnaes Ruth , Crespo Mateus , Zafeiriou Zafeiris , Sumanasuriya Semini , Bianchini Diletta , Hunt Joanne , Moloney Deirdre , Perez-Lopez Raquel , Tunariu Nina , Miranda Susana , Figueiredo Inês , Ferreira Ana , Christova Rossitza , Gil Veronica , Aziz Sara , Bertan Claudia , de Oliveira Flavia M. , Atkin Mark , Clarke Matthew , Goodall Jane , Sharp Adam , MacDonald Theresa , Rubin Mark A. , Yuan Wei , Barbieri Christopher E. , Carreira Suzanne , Mateo Joaquin , de Bono Johann S.
Published: April 2023

SPOP mutation identified in this cohort.
Supplementary Figure 8 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 8
Figure S2 from SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy
Authors: Wang Feng , Xia Xiaojun , Yang Chunying , Shen Jianliang , Mai Junhua , Kim Han-Cheon , Kirui Dickson , Kang Ya'an , Fleming Jason B. , Koay Eugene J. , Mitra Sankar , Ferrari Mauro , Shen Haifa
Published: April 2023

Figure S2. SMAD4 depletion induced high level of autophagy in response to ionizing radiation in Panc-1 cells using shRNA lentiviral vector. Immunoblot of LC3 isoforms were measured using antibody against LC3 in Panc-1-CTL, Panc-1-sh-SMAD4-#2 Cells. (A) The protein level of the β-actin was used as the internal standard.(B) Representative confocal images of endogenous LC3 staining in Panc-1 transfected with control shRNA lentiviral or shRNA lentiviral vector against SMAD4, and treated with or without IR (6 Gy). Cells were stained with antibody to LC3 (red) and DAPI (blue).
Supplementary Figure 1 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 1
Supplementary Figures from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
Authors: Leal Mariana Ferreira , Haynes Ben P. , Schuster Eugene , Yeo Belinda , Afentakis Maria , Zabaglo Lila , Martins Vera , Buus Richard , Dodson Andrew , Cheang Maggie C.U. , Smith Ian E. , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Supplementary Figures S1-S7
Supplementary Methods from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Authors: Ramakrishna Sneha , Highfill Steven L. , Walsh Zachary , Nguyen Sang M. , Lei Haiyan , Shern Jack F. , Qin Haiying , Kraft Ira L. , Stetler-Stevenson Maryalice , Yuan Constance M. , Hwang Jennifer D. , Feng Yang , Zhu Zhongyu , Dimitrov Dimiter , Shah Nirali N. , Fry Terry J.
Published: April 2023

Supplementary methods to paper
Table S7 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S7
Supplementary Figure 2 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Plasma-Based Detection of Microsatellite Instability and High Tumor Mutation Burden in Patients with Sufficient Circulating Tumor DNA.
Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Authors: Ormhøj Maria , Scarfò Irene , Cabral Maria L. , Bailey Stefanie R. , Lorrey Selena J. , Bouffard Amanda A. , Castano Ana P. , Larson Rebecca C. , Riley Lauren S. , Schmidts Andrea , Choi Bryan D. , Andersen Rikke S. , Cédile Oriane , Nyvold Charlotte G. , Christensen Jacob H. , Gjerstorff Morten F. , Ditzel Henrik J. , Weinstock David M. , Barington Torben , Frigault Matthew J. , Maus Marcela V.
Published: April 2023

Supplementary Materials and Data
Figure S04 from Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Authors: Hutchinson Katherine E. , Yost Susan E. , Chang Ching-Wei , Johnson Radia Marie , Carr Adrian R. , McAdam Paul R. , Halligan Daniel L. , Chang Chun-Chieh , Schmolze Daniel , Liang Jackson , Yuan Yuan
Published: April 2023

Supplementary KEGG, GO terms, GSEA analyses
Supplementary Figure Legends from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Authors: Gartrell Robyn D. , Marks Douglas K. , Rizk Emanuelle M. , Bogardus Margaret , Gérard Camille L. , Barker Luke W. , Fu Yichun , Esancy Camden L. , Li Gen , Ji Jiayi , Rui Shumin , Ernstoff Marc S. , Taback Bret , Pabla Sarabjot , Chang Rui , Lee Sandra J. , Krolewski John J. , Morrison Carl , Horst Basil A. , Saenger Yvonne M.
Published: April 2023

Figure legends for supplementary figures.
Supplemental Table 9 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Authors: Mao Pingping , Cohen Ofir , Kowalski Kailey J. , Kusiel Justin G. , Buendia-Buendia Jorge E. , Cuoco Michael S. , Exman Pedro , Wander Seth A. , Waks Adrienne G. , Nayar Utthara , Chung Jon , Freeman Samuel , Rozenblatt-Rosen Orit , Miller Vincent A. , Piccioni Federica , Root David E. , Regev Aviv , Winer Eric P. , Lin Nancy U. , Wagle Nikhil
Published: April 2023

RNA-seq experiment conditions and QC stats
Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Authors: Mao Pingping , Cohen Ofir , Kowalski Kailey J. , Kusiel Justin G. , Buendia-Buendia Jorge E. , Cuoco Michael S. , Exman Pedro , Wander Seth A. , Waks Adrienne G. , Nayar Utthara , Chung Jon , Freeman Samuel , Rozenblatt-Rosen Orit , Miller Vincent A. , Piccioni Federica , Root David E. , Regev Aviv , Winer Eric P. , Lin Nancy U. , Wagle Nikhil
Published: April 2023

FGFR alterations in different cohorts
Supplementary Data from Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Authors: Isomoto Kohsuke , Haratani Koji , Hayashi Hidetoshi , Shimizu Shigeki , Tomida Shuta , Niwa Takashi , Yokoyama Toshihide , Fukuda Yasushi , Chiba Yasutaka , Kato Ryoji , Tanizaki Junko , Tanaka Kaoru , Takeda Masayuki , Ogura Takashi , Ishida Tadashi , Ito Akihiko , Nakagawa Kazuhiko
Published: April 2023

Supplementary_Tables
Supplementary Figure S7 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S7. Mean changes from baseline by study arm in Functional Assessment of Cancer Therapy-Colorectal [FACT-C].
Supplementary Figure S5 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S5. Mean changes from baseline by study arm in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 global quality of life and functional scales.
Supplementary Figure S4 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S4. Compliance to quality of life questionnaires (number of patients completing baseline assessments and the assessments at designated time points). Panel A: EORTC QLQ-C30. Panel B: FACT-C
Supplementary Data from CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer
Authors: Williams Edward H. , Flint Thomas R. , Connell Claire M. , Giglio Daniel , Lee Hassal , Ha Taehoon , Gablenz Eva , Bird Nicholas J. , Weaver James M.J. , Potts Harry , Whitley Cameron T. , Bookman Michael A. , Lynch Andy G. , Meyer Hannah V. , Tavaré Simon , Janowitz Tobias
Published: April 2023

Supplemental Materials
Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Authors: Davids Matthew S. , Kuss Bryone J. , Hillmen Peter , Montillo Marco , Moreno Carol , Essell James , Lamanna Nicole , Nagy Zsolt , Tam Constantine S. , Stilgenbauer Stephan , Ghia Paolo , Delgado Julio , Lustgarten Stephanie , Weaver David T. , Youssoufian Hagop , Jäger Ulrich
Published: April 2023

â€¢Table S1 shows a summary of prior anticancer therapies received by all patients in the study â€¢Table S2 shows best overall response, overall response rate, and duration of response by investigator in the study population of patients while receiving ofatumumab in the parent DUO study before crossover â€¢Table S3 shows rates of all serious TEAEs and individual hematologic and non-hematologic serious TEAEs in {greater than or equal to} 2% of patients in the study population â€¢ Table S4 shows rates of all TEAEs leading to death in patients in the study population â€¢Table S5 shows a summary of patient disposition information
Supplementary Data from Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice
Authors: Montay-Gruel Pierre , Acharya Munjal M. , Gonçalves Jorge Patrik , Petit Benoît , Petridis Ioannis G. , Fuchs Philippe , Leavitt Ron , Petersson Kristoffer , Gondré Maude , Ollivier Jonathan , Moeckli Raphael , Bochud François , Bailat Claude , Bourhis Jean , Germond Jean-François , Limoli Charles L. , Vozenin Marie-Catherine
Published: April 2023

Supplementary Figure 1: Tumor growth delay of U87 orthotopic GBM implanted in the striatum of female Nude mice measured by contrast-enhanced Cone Beam CT
Figure S8 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Authors: Vázquez-Borrego Mari C. , Gupta Vandana , Ibáñez-Costa Alejandro , Gahete Manuel D. , Venegas-Moreno Eva , Toledano-Delgado Álvaro , Cano David A. , Blanco-Acevedo Cristóbal , Ortega-Salas Rosa , Japón Miguel A. , Barrera-Martín Ana , Vasiljevic Alexandre , Hill Jason , Zhang Shengwen , Halem Heather , Solivera Juan , Raverot Gérald , Gálvez María A. , Soto-Moreno Alfonso , Paez-Pereda Marcelo , Culler Michael D. , Castaño Justo P. , Luque Raúl M.
Published: April 2023

Direct effect of BIM-355 at different doses on tumor growth in POMC-KO mice model.
Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Authors: Chen Xiaoji , Dong Zhao , Hubbell Earl , Kurtzman Kathryn N. , Oxnard Geoffrey R. , Venn Oliver , Melton Collin , Clarke Christina A. , Shaknovich Rita , Ma Ting , Meixiong Gerry , Seiden Michael V. , Klein Eric A. , Fung Eric T. , Liu Minetta C.
Published: April 2023

Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Figure S3 from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary Figure 3. MALDI-MS of TIGITAb and DFO-TIGITAb demonstrating successful bioconjugation.
Table S1 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Authors: Di Giacomo Anna Maria , Chiarion-Sileni Vanna , Del Vecchio Michele , Ferrucci Pier Francesco , Guida Michele , Quaglino Pietro , Guidoboni Massimo , Marchetti Paolo , Cutaia Ornella , Amato Giovanni , Covre Alessia , Camerini Roberto , Calabrò Luana , Valente Monica , Giannarelli Diana , Mandalà Mario , Maio Michele
Published: April 2023

Maintenance phase treatment exposure
Supplementary Tables from Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy
Authors: Ma Lin , Gonzalez-Junca Alba , Zheng Yufei , Ouyang Haoxu , Illa-Bochaca Irineu , Horst Kathleen C. , Krings Gregor , Wang Yinghao , Fernandez-Garcia Ignacio , Chou William , Barcellos-Hoff Mary Helen
Published: April 2023

Supplementary tables 1-3
Supplementary Figures Legends from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Authors: Ranganathan Raghuveer , Shou Peishun , Ahn Sarah , Sun Chuang , West John , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplementary Figures Legends
Fig S4 from Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy
Authors: Ma Lin , Gonzalez-Junca Alba , Zheng Yufei , Ouyang Haoxu , Illa-Bochaca Irineu , Horst Kathleen C. , Krings Gregor , Wang Yinghao , Fernandez-Garcia Ignacio , Chou William , Barcellos-Hoff Mary Helen
Published: April 2023

Supplementary Figure 4. Macrophage differentiation from circulating human PBMC.
Supplementary Data from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
Authors: Fontana Francesca , Scott Michael J. , Allen John S. , Yang Xiaoxia , Cui Grace , Pan Dipanjan , Yanaba Noriko , Fiala Mark A. , O'Neal Julie , Schmieder-Atteberry Anne H. , Ritchey Julie , Rettig Michael , Simons Kathleen , Fletcher Steven , Vij Ravi , DiPersio John F. , Lanza Gregory M.
Published: April 2023

Supplemental Figure legends
Suppl Figure 2 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
Authors: Fontana Francesca , Scott Michael J. , Allen John S. , Yang Xiaoxia , Cui Grace , Pan Dipanjan , Yanaba Noriko , Fiala Mark A. , O'Neal Julie , Schmieder-Atteberry Anne H. , Ritchey Julie , Rettig Michael , Simons Kathleen , Fletcher Steven , Vij Ravi , DiPersio John F. , Lanza Gregory M.
Published: April 2023

Supplemental Figure 2 color
Figure S3 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

Additional example of patient experiencing immune-related pseudoprogression (PsP)
Figure S1 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

iRANO Response Rubric.
Supplementary Figure 6 from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Authors: Mudianto Tenny , Campbell Katie M. , Webb Jason , Zolkind Paul , Skidmore Zachary L. , Riley Rachel , Barnell Erica K. , Ozgenc Ibrahim , Giri Tusar , Dunn Gavin P. , Adkins Douglas R. , Griffith Malachi , Egloff Ann Marie , Griffith Obi L. , Uppaluri Ravindra
Published: April 2023

Supplementary Figure 6
Supplementary Figure 5 from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Authors: Mudianto Tenny , Campbell Katie M. , Webb Jason , Zolkind Paul , Skidmore Zachary L. , Riley Rachel , Barnell Erica K. , Ozgenc Ibrahim , Giri Tusar , Dunn Gavin P. , Adkins Douglas R. , Griffith Malachi , Egloff Ann Marie , Griffith Obi L. , Uppaluri Ravindra
Published: April 2023

Supplementary Figure 5
Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

Supplemental Fig. 3. CLL-CI correlates with EFS in patient subgroups (validation set).
Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

Supplemental Figure 2. CLL-CI correlates with OS across CLL patient subgroups (derivation dataset).
Table S1 from Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation
Authors: Hayden Elizabeth R. , Chen Mingqing , Pasquariello Kyle Z. , Gibson Alice A. , Petti James J. , Shen Shichen , Qu Jun , Ong Su Sien , Chen Taosheng , Jin Yan , Uddin Muhammad Erfan , Huang Kevin M. , Paz Aviv , Sparreboom Alex , Hu Shuiying , Sprowl Jason A.
Published: April 2023

Mean {plus minus} SEM change of 8FcA uptake (Mean difference) in OATP1B1 overexpressing HEK293 cells between vehicle (DMSO) and exposure to FDA approved TKIs. Statistical significance was measured by ANOVA and Fisher's LSD test.
Table S2 from Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer
Authors: Porciuncula Angelo , Morgado Micaela , Gupta Richa , Syrigos Kostas , Meehan Robert , Zacharek Sima J. , Frederick Joshua P. , Schalper Kurt A.
Published: April 2023

Supplementary Table S2
Supplementary Figure S3 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S3. Differentiation of ML NK cells and Preactivated-Expanded CB-NK cells.
Table S1 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
Authors: Tong Kit I. , Yoon Sharon , Isaev Keren , Bakhtiari Mehran , Lackraj Tracy , He Michael Y. , Joynt Jesse , Silva Anjali , Xu Maria C. , Privé Gilbert G. , He Housheng Hansen , Tiedemann Rodger E. , Chavez Elizabeth A. , Chong Lauren C. , Boyle Merrill , Scott David W. , Steidl Christian , Kridel Robert
Published: April 2023

Results from CRISPR/Cas9 knockout screen in SU-DHL-4 cells.
Supplementary Figure S2 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S2 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 17 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

SR18292, an inhibitor of PGC1α reduces the co-expression of PGC1α and PPARγ in IPMN cells.
Figure S7 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Authors: Corso Simona , Pietrantonio Filippo , Apicella Maria , Migliore Cristina , Conticelli Daniela , Petrelli Annalisa , D'Errico Laura , Durando Stefania , Moya-Rull Daniel , Bellomo Sara E. , Ughetto Stefano , Degiuli Maurizio , Reddavid Rossella , Fumagalli Uberto , De Pascale Stefano , Sgroi Giovanni , Rausa Emanuele , Baiocchi Gian Luca , Molfino Sarah , De Manzoni Giovanni , Bencivenga Maria , Siena Salvatore , Sartore-Bianchi Andrea , Morano Federica , Corallo Salvatore , Prisciandaro Michele , Di Bartolomeo Maria , Gloghini Annunziata , Marsoni Silvia , Sottile Antonino , Sapino Anna , Marchiò Caterina , Dahle-Smith Asa , Miedzybrodzka Zosia , Lee Jessica , Ali Siraj M. , Ross Jeffrey S. , Alexander Brian M. , Miller Vincent A. , Petty Russell , Schrock Alexa B. , Giordano Silvia
Published: April 2023

Supplementary Figure 7
Table S3 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
Authors: Seitter Samantha J. , Sherry Richard M. , Yang James C. , Robbins Paul F. , Shindorf Mackenzie L. , Copeland Amy R. , McGowan Christine T. , Epstein Monica , Shelton Thomas E. , Langhan Michelle M. , Franco Zulmarie , Danforth David N. , White Donald E. , Rosenberg Steven A. , Goff Stephanie L.
Published: April 2023

Table S3 describes treatment-related adverse events
Supplementary Figure S3 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S3 provides Bland-Altman plots showing correlation between ctDNA fraction estimates derived based on 72-gene panel somatic mutations and whole exome copy number profiles.
Supplementary Figure 2 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Authors: Crabb Simon J. , Danson Sarah , Catto James W.F. , Hussain Syed , Chan Danna , Dunkley Denise , Downs Nichola , Marwood Ellice , Day Laura , Saunders Geoff , Light Michelle , Whitehead Amy , Ellis Deborah , Sarwar Naveed , Enting Deborah , Birtle Alison , Johnson Bernadette , Huddart Robert , Griffiths Gareth
Published: April 2023

Supplementary Figure 2 shows CONSORT diagrams for both phases of the trial
Supplementary Data Protocol from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Authors: Crabb Simon J. , Danson Sarah , Catto James W.F. , Hussain Syed , Chan Danna , Dunkley Denise , Downs Nichola , Marwood Ellice , Day Laura , Saunders Geoff , Light Michelle , Whitehead Amy , Ellis Deborah , Sarwar Naveed , Enting Deborah , Birtle Alison , Johnson Bernadette , Huddart Robert , Griffiths Gareth
Published: April 2023

Redacted protocol for supplementary files
Supplementary Figure S2 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S2 shows examples of cfDNA whole exome copy number profiles where accurate ctDNA fraction estimation is more challenging due to significant subclonal heterogeneity or low ctDNA fraction.
Supplementary Figure S18 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S18 provides whole exome copy number profiles in patients that did not show temporal changes in their 72-gene copy number profile
Supplementary Figure S17 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S17 provides whole exome somatic mutation profiles in patients that did not show temporal changes in 72-gene panel mutation profiles
Supplementary Figure 2 from FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC
Authors: Bickett Thomas E. , Knitz Michael , Darragh Laurel B. , Bhatia Shilpa , Van Court Benjamin , Gadwa Jacob , Bhuvane Shiv , Piper Miles , Nguyen Diemmy , Tu Hua , Lenz Laurel , Clambey Eric T. , Barry Kevin , Karam Sana D.
Published: April 2023

Supplementary Figure 2 (A) Flow cytometry analysis of LY2 tumors analyzing DC populations; n=6. (B) Analysis of FLT3L present in the serum of LY2 bearing mice treated with radiation therapy and isotype antibodies, radiation therapy and anti-CD25 antibody, radiation therapy and anti-CD25 antibody and anti-asialoGM1 antibody to deplete NK cells, and radiation therapy, anti-CD25 antibody, anti-asialoGM1 antibody to deplete NK cells, and FLT3L therapy; n=5.
Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Authors: Conforti Fabio , Pala Laura , Pagan Eleonora , Bagnardi Vincenzo , De Pas Tommaso , Queirolo Paola , Pennacchioli Elisabetta , Catania Chiara , Cocorocchio Emilia , Ferrucci Pier Francesco , Saponara Maristella , Orsolini Gianmarco , Zagami Paola , Nicoló Eleonora , De Marinis Filippo , Tortora Giampaolo , Bria Emilio , Minucci Saverio , Joffe Hadine , Veronesi Paolo , Wargo Jennifer , Rosenthal Rachel , Swanton Charles , Mantovani Alberto , Gelber Richard D. , Viale Giuseppe , Goldhirsch Aron , Giaccone Giuseppe
Published: April 2023

Supplementary Table S3
Supplementary Fig. 16 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

PDAC prediction accuracy using various number of DMRs identified from PDAC vs. healthy plasma sample analysis
Supplementary Fig. 11 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

CRC prediction accuracy using various number of DMRs identified from CRC vs. healthy plasma sample analysis
Supplementary Fig. 10 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Comparison of several machine learning classifiers
Supplementary table 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Fractions of circulating CD8+ T-cell subsets in mUC patients with and without a tumor response to anti-PD1
Supplementary figure 9 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Proposed mechanism of action of pembrolizumab in mUC patients
Supplementary Legend from Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Authors: Schwartz Christopher J. , da Silva Edaise M. , Marra Antonio , Gazzo Andrea M. , Selenica Pier , Rai Vikas K. , Mandelker Diana , Pareja Fresia , Misyura Maksym , D'Alfonso Timothy M. , Brogi Edi , Drullinsky Pamela , Razavi Pedram , Robson Mark E. , Drago Joshua Z. , Wen Hannah Y. , Zhang Liying , Weigelt Britta , Shia Jinru , Reis-Filho Jorge S. , Zhang Hong
Published: April 2023

Supplementary Legend
Supplementary Data from Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Authors: Schwartz Christopher J. , da Silva Edaise M. , Marra Antonio , Gazzo Andrea M. , Selenica Pier , Rai Vikas K. , Mandelker Diana , Pareja Fresia , Misyura Maksym , D'Alfonso Timothy M. , Brogi Edi , Drullinsky Pamela , Razavi Pedram , Robson Mark E. , Drago Joshua Z. , Wen Hannah Y. , Zhang Liying , Weigelt Britta , Shia Jinru , Reis-Filho Jorge S. , Zhang Hong
Published: April 2023

Supplementary Figure 2. Comparison of the most frequently mutated cancer genes in the Lynch syndrome BC cohort and in non Lynch Syndrome BCs matched by clinicopathologic characteristics.
Table S1-S7 from Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification
Authors: Lindgaard Sidsel C. , Sztupinszki Zsófia , Maag Emil , Chen Inna M. , Johansen Astrid Z. , Jensen Benny V. , Bojesen Stig E. , Nielsen Dorte L. , Hansen Carsten P. , Hasselby Jane P. , Nielsen Kaspar R. , Szallasi Zoltan , Johansen Julia S.
Published: April 2023

Supplementary tables S1-S7 show extra details from the manuscript, including the full list of proteins in the Olink Immuno-oncology assay as well as statistical details from the two indices, and a table of recent similar studies.
Figure S4 from Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification
Authors: Lindgaard Sidsel C. , Sztupinszki Zsófia , Maag Emil , Chen Inna M. , Johansen Astrid Z. , Jensen Benny V. , Bojesen Stig E. , Nielsen Dorte L. , Hansen Carsten P. , Hasselby Jane P. , Nielsen Kaspar R. , Szallasi Zoltan , Johansen Julia S.
Published: April 2023

Supplementary figure S4 shows ROC curves for the Olink panel, excluding CA19-9 in the analyses
Supplementary Data from A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Authors: Hu Jethro L. , Omofoye Oluwaseun A. , Rudnick Jeremy D. , Kim Sungjin , Tighiouart Mourad , Phuphanich Surasak , Wang Hongqiang , Mazer Mia , Ganaway Toni , Chu Ray M. , Patil Chirag G. , Black Keith L. , Shiao Stephen L. , Wang Rongfu , Yu John S.
Published: April 2023

Supplementary Data from A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Authors: Sinn Bruno V. , Loibl Sibylle , Hanusch Claus A. , Zahm Dirk-Michael , Sinn Hans-Peter , Untch Michael , Weber Karsten , Karn Thomas , Becker Clemens , Marmé Frederik , Schmitt Wolfgang D. , Müller Volkmar , Schem Christian , Treue Denise , Stickeler Elmar , Klauschen Frederik , Burchardi Nicole , Furlanetto Jenny , van Mackelenbergh Marion , Fasching Peter A. , Schneeweiss Andreas , Denkert Carsten
Published: April 2023

Bivariate logistic regression models for the immune- and proliferation-associated gene signatures
Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Authors: Sinn Bruno V. , Loibl Sibylle , Hanusch Claus A. , Zahm Dirk-Michael , Sinn Hans-Peter , Untch Michael , Weber Karsten , Karn Thomas , Becker Clemens , Marmé Frederik , Schmitt Wolfgang D. , Müller Volkmar , Schem Christian , Treue Denise , Stickeler Elmar , Klauschen Frederik , Burchardi Nicole , Furlanetto Jenny , van Mackelenbergh Marion , Fasching Peter A. , Schneeweiss Andreas , Denkert Carsten
Published: April 2023

Patients were randomized to receive one injection durvalumab 0.75 g i.v. or placebo two weeks prior to start of chemotherapy (window trial). This was followed by nab-paclitaxel 125 mg/m2 weekly for 12 weeks with durvalumab 1.5 g i.v. or placebo every 4 weeks. This was followed by epirubicin/cyclophosphamide every two weeks for four cycles with durvalumab or placebo every four weeks. After an amendment, the window phase was stopped, and all patients started with chemotherapy and durvalumab/placebo on day one. Formalin-fixed and paraffin-embedded core biopsy samples were collected prior to randomization (mandatory).
Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Authors: Ansell Stephen M. , Maris Michael B. , Lesokhin Alexander M. , Chen Robert W. , Flinn Ian W. , Sawas Ahmed , Minden Mark D. , Villa Diego , Percival Mary-Elizabeth M. , Advani Anjali S. , Foran James M. , Horwitz Steven M. , Mei Matthew G. , Zain Jasmine , Savage Kerry J. , Querfeld Christiane , Akilov Oleg E. , Johnson Lisa D.S. , Catalano Tina , Petrova Penka S. , Uger Robert A. , Sievers Eric L. , Milea Anca , Roberge Kathleen , Shou Yaping , O'Connor Owen A.
Published: April 2023

Study Schema
Supplementary Methods from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Supplementary Methods
Figure S4 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Dynamic changes of TF and CNI in patients receiving front line chemotherapy. Bar plots of average percentage distribution of TF (A, B) or CNI (C, D) values in plasma of HGS-EOC at T=0 and at different time points of the "treatment window" (A0 to A1, and N0 to N4). Data are separated according to the different protocols they received: panels A, and C depict patients receiving CT while panels B and D depict patients receiving NACT protocol. Within each box, the horizontal line represents the median distribution, the box margins the 25% and 75% percentiles, and the whiskers the 5% and 95% percentiles. Blue circles, Pt-ps patients. Red circles, Pt-r patients. Green circles, Pt-s patients. *, p< 0.05; ** p <0.01; *** p<0.001, according to the Mann-Whitney test.
Figure S11 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.